Evidence map›Paper›PMID 40526902›Full record

SynthesisJMIR public health and surveillance2025

Minimum Data Set and Metadata for Active Vaccine Safety Surveillance: Systematic Review.

Mengdi Zhang, Junting Yang, Yan Li, Yuan Li, Tong Li, Ziqi Dong, Shuo Gong, Yahui Wu, Minrui Ren, Chunxiang Fan and 9 more

Abstract readSystematic Review
In one paragraph

Synthesis in JMIR public health and surveillance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Mengdi ZhangDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Haidian District, Beijing, 100191, China, 86 10-82805162, 86 10-82805162.ORCID 0009-0003-1746-5146
Junting YangDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Haidian District, Beijing, 100191, China, 86 10-82805162, 86 10-82805162.ORCID 0009-0003-1264-4663
Yan LiNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.ORCID 0000-0002-7365-6348
Yuan LiNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.ORCID 0009-0003-6408-2762
Tong LiDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Haidian District, Beijing, 100191, China, 86 10-82805162, 86 10-82805162.ORCID 0009-0009-6087-669X
Ziqi DongDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Haidian District, Beijing, 100191, China, 86 10-82805162, 86 10-82805162.ORCID 0009-0003-1567-3523
Shuo GongDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Haidian District, Beijing, 100191, China, 86 10-82805162, 86 10-82805162.ORCID 0009-0002-4594-1608
Yahui WuDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Haidian District, Beijing, 100191, China, 86 10-82805162, 86 10-82805162.ORCID 0009-0002-3233-3777
Minrui RenNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.ORCID 0000-0001-6412-0923
Chunxiang FanNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.ORCID 0009-0007-0855-2968
Lina ZhangNational Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.ORCID 0009-0009-8674-9525
Yi WangCenter for Drug Reevaluation, National center for ADR Monitoring, Beijing, China.ORCID 0009-0004-8788-8459
Yali WangCenter for Drug Reevaluation, National center for ADR Monitoring, Beijing, China.ORCID 0009-0003-9786-033X
Jingtian RenCenter for Drug Reevaluation, National center for ADR Monitoring, Beijing, China.ORCID 0009-0000-3554-7135
Feng SunDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Haidian District, Beijing, 100191, China, 86 10-82805162, 86 10-82805162.ORCID 0000-0003-4334-6805
Chuanyong ShenCenter for Drug Reevaluation, National center for ADR Monitoring, Beijing, China.ORCID 0009-0001-9221-3884
Keli Li *National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.ORCID 0000-0001-9745-070X
Zhike Liu *Department of Epidemiology and Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Haidian District, Beijing, 100191, China, 86 10-82805162, 86 10-82805162.ORCID 0000-0002-3232-8196
Siyan Zhan *Department of Epidemiology and Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Haidian District, Beijing, 100191, China, 86 10-82805162, 86 10-82805162.ORCID 0000-0001-7252-5349

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Active vaccine safety surveillance (AVSS) stands as a top priority for the World Health Organization (WHO), serving as a critical indicator of the fourth maturity level for national regulatory agencies. Objective: This review aims to define the minimal data scope for association studies in vaccine safety, providing a reference framework for implementing AVSS systems worldwide, especially in low- and middle-income countries. Methods: The study systematically searched PubMed, Embase, and Web of Science for cohort and case-control studies related to AVSS published between January 1, 2018, and September 7, 2022. Guided by the WHO and Council for International Organizations of Medical Sciences guidelines (CIOMS), we developed a 4D framework for Minimum Data Sets (MDSs), including "Vaccine," "Outcome," "Demographic Data," and "Covariate." Variables with a frequency of at least 5% were included in the MDS. Results: Of the 123 included studies, 102 (82.9%) were cohort studies and 98 (79.7%) originated from high-income countries, covering populations across the entire life course. The MDS for COVID-19 vaccines identified 54 variables, while the MDS for maternal populations included 96 variables. WHO guidelines were found to align better with practical applications compared to CIOMS guidelines, though both require further optimization based on the MDS findings. However, metadata for these essential variables were inadequately described across the studies. Conclusions: The proposed MDS provides clear guidance and concise requirements for AVSS data scope. Establishing a globally standardized MDS and comprehensive metadata based on these findings is essential to enhancing the global vaccine safety ecosystem.

Indexed as

COVID-19 VaccinesDatasets as TopicMetadataVaccinesCOVID-19HumansWorld Health OrganizationCOVID-19 VaccinesVaccinesactive surveillanceassociationmetadataminimum data setsvaccine safety

Identifiers

PMID40526902
PMCPMC12187031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.